Expanding Germline Genetic Testing in Breast Cancer: Universal versus ASCO-Guided Approaches
Asian Journal of Current Research in Clinical Cancer · 2026 · 6 (1) · 18-26
DOI: 10.51847/gouduiysfo ↗Kurz gefasst
Fachartikel in der Zeitschrift Asian Journal of Current Research in Clinical Cancer, 2026. Verfasst von Maria Silva und 1 weiteren Autor:innen. Die Arbeit nennt 52 Literaturangaben.
Abstract (Originalsprache)
A notable fraction of breast cancer occurrences stems from hereditary pathogenic mutations. Germline genetic testing (GGT), especially focused on BRCA1 and BRCA2, is an indispensable component of precision oncology, enabling tailored risk classification and the formulation of individualized treatment plans. Within this report, we investigate the practicality of performing blanket testing on all freshly diagnosed breast cancer patients, without regard for age, personal or familial cancer backgrou
Zitieren
APA
Silva, M., & Pereira, J. (2026). Expanding Germline Genetic Testing in Breast Cancer: Universal versus ASCO-Guided Approaches. Asian Journal of Current Research in Clinical Cancer, 6(1), 18-26. https://doi.org/10.51847/gouduiysfo
Vancouver
Silva M, Pereira J. Expanding Germline Genetic Testing in Breast Cancer: Universal versus ASCO-Guided Approaches. Asian Journal of Current Research in Clinical Cancer. 2026;6(1):18-26. doi:10.51847/gouduiysfo
BibTeX
@article{Silva2026,
author = {Silva, Maria and Pereira, Joao},
title = {Expanding Germline Genetic Testing in Breast Cancer: Universal versus ASCO-Guided Approaches},
journal = {Asian Journal of Current Research in Clinical Cancer},
year = {2026},
volume = {6},
number = {1},
pages = {18--26},
doi = {10.51847/gouduiysfo}
}
EUVIMED